方法：回顾性分析2011-07/2015-04间在我院玻璃体腔注射ranibizumab治疗非AMD脉络膜新生血管的疗效及眼部与全身不良反应。治疗前后均进行裂隙灯的检查、最佳矫正视力的测定、荧光素眼底血管造影(fluorescein fundus angiography， FFA)、光学相干性断层扫描(optical coherence tomography，OCT)，治疗后分别观察注射次数及术前和术后(末次随访时)患者的最佳矫正视力、黄斑区1 mm直径视网膜最大厚度。

结果：随访6mo～3a，治疗后平均视力(4.77±0.24)与治疗前(4.50±0.34)相比差异具有统计学意义(P<0.01)，黄斑区1mm直径最大厚度(317.62±55.05μm)较术前(421.63±139.37μm)相比差异具有统计学意义(P<0.01)。平均治疗次数为2.6±1.3次。患眼治疗后均未发生眼内炎、青光眼、视网膜脱离、葡萄膜炎等并发症及全身不良反应。

结论：Ranibizumab治疗非AMD脉络膜新生血管有效、不良反应低。

METHODS:Continous cases that had been diagnosed as CNV in non-AMD patients from July 2011 to October 2015 and accepted intravitreal injection of ranibizumab were retrospective analyzed for the efficacy and systemic adverse reactions. The slit lamp examination, best-correct visual acuity(BCVA), fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were conducted before and after treatment. the injection number, BCVA and the central macular thickness(CMT)within diameter of 1mm at macula before and after treatment were observed.

RESULTS:The follow-up duration was 6mo to 3a in total 22 patients with 24 eyes. The BCVA was 4.50±0.34 at baseline and was improved significantly to 4.77±0.24 after treatment(P<0.01). Mean CMT decreased from 421.63±139.37μm at baseline to 317.62±55.05μm at the final follow-up(P<0.01). The average injection number was 2.6±1.3. None ocular complications and systematic side effects were observed in all cases, such as endophthalmitis, glaucoma, retinal detachment or uveitis.

CONCLUSION:The intravitreal injection of ranibizumab for CNV in non-AMD patients is effective with few side effects.